No­var­tis pe­ti­tions Supreme Court in ef­fort to 'vig­or­ous­ly de­fend' Gilenya patent

No­var­tis has of­fi­cial­ly pe­ti­tioned the Supreme Court in an on­go­ing ef­fort to pro­tect Gilenya from gener­ic ri­vals for at least an­oth­er sev­er­al years.

The Swiss phar­ma gi­ant filed the 55-page doc­u­ment Wednes­day, af­ter an­nounc­ing its in­tent to pe­ti­tion the court in Sep­tem­ber. The case dates back to 2016, when HEC Pharm filed for gener­ic ap­proval of its own ver­sion of Gilenya, No­var­tis’s block­buster mul­ti­ple scle­ro­sis drug. The gener­ic won ap­proval in 2019, but No­var­tis fought back with law­suits as­sert­ing that var­i­ous patents don’t ex­pire un­til 2027.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER